Bostongene Corporation

Waltham, MA

UEI
PP3RJC2N6528
CAGE
7LKK4
Primary NAICS
541380 Testing Laboratories and Services
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
SAM.gov registration date
Physical address
Parking lot, 95 Sawyer Rd # 500, Waltham, MA 02453, USA
Website
bostongene.com
Founded
2015
Employees
251-1K
Estimated annual revenue
$50M-$100M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Bostongene Corporation's 2 most recent federal contract and grant awards, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
Deep sequencing analysis services to monitor copanlisib/rituximab combination treatment Contract · 75N91024P00398 National Cancer Institute $302,039
Multi-omic analyses for the comprehensive interrogation of tumors with the smart system Contract · 75N91023P00078 National Cancer Institute $200,000

Quick answers

What is Bostongene Corporation's UEI?

Bostongene Corporation's Unique Entity ID (UEI) in SAM.gov is PP3RJC2N6528.

What is Bostongene Corporation's CAGE code?

Bostongene Corporation's CAGE code is 7LKK4.

What is Bostongene Corporation's primary NAICS code?

Bostongene Corporation's primary NAICS code is 541380 (Testing Laboratories and Services).

Where is Bostongene Corporation located?

Bostongene Corporation's physical address in SAM.gov is Parking lot, 95 Sawyer Rd # 500, Waltham, MA 02453, USA.

Is Bostongene Corporation registered in SAM.gov?

Bostongene Corporation's SAM.gov registration expired on September 3, 2026.

What is Bostongene Corporation's most recent federal award?

Bostongene Corporation's most recent federal contract award is Deep sequencing analysis services to monitor copanlisib/rituximab combination treatment (75N91024P00398), from National Cancer Institute, on September 16, 2024.

On GovTribe

See Bostongene Corporation's full federal record

  • Federal contract awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login